George Lloyd Sells 132,426 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP George Lloyd sold 132,426 shares of the company’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $38.34, for a total transaction of $5,077,212.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Royalty Pharma Price Performance

NASDAQ RPRX traded up $0.53 during mid-day trading on Friday, hitting $38.92. The stock had a trading volume of 3,164,604 shares, compared to its average volume of 4,278,617. The firm’s 50 day moving average is $36.99 and its 200 day moving average is $35.84. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. The stock has a market capitalization of $22.47 billion, a price-to-earnings ratio of 29.48, a PEG ratio of 2.04 and a beta of 0.56. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $41.24.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.06. The business had revenue of $609.29 million for the quarter, compared to analysts’ expectations of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. Equities research analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, November 14th. Royalty Pharma’s dividend payout ratio (DPR) is presently 66.67%.

Analyst Ratings Changes

RPRX has been the topic of a number of research analyst reports. The Goldman Sachs Group started coverage on Royalty Pharma in a research report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 target price on the stock. Weiss Ratings cut Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Morgan Stanley cut their price objective on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. TD Cowen cut Royalty Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Capital International Investors lifted its position in Royalty Pharma by 24.4% in the third quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company’s stock valued at $960,064,000 after acquiring an additional 5,332,074 shares during the last quarter. Norges Bank purchased a new position in shares of Royalty Pharma during the second quarter worth about $181,388,000. Dorsey Asset Management LLC acquired a new stake in shares of Royalty Pharma during the third quarter worth about $82,924,000. Qube Research & Technologies Ltd lifted its holdings in shares of Royalty Pharma by 737.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 2,481,771 shares of the biopharmaceutical company’s stock valued at $87,557,000 after purchasing an additional 2,185,366 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Royalty Pharma by 379.2% in the 3rd quarter. Millennium Management LLC now owns 2,235,133 shares of the biopharmaceutical company’s stock valued at $78,855,000 after purchasing an additional 1,768,702 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.